Magazine Article | October 30, 2020

Paragraph IV Patent Challenges During COVID-19: What's Next?

Source: Life Science Leader

By Molly Bowman

Just over a year ago, the conversation about generics centered on the number and pace of generic drug approvals by the FDA, including the amount of patent challenge activity that was signaling a very competitive generics marketplace for the products in question.

The FDA has prioritized increasing competition in the generics market to control costs, which has translated to prioritized reviews of ANDA applications for generic drugs. Paragraph IV (i.e., “[a generic applicant certifying] in its ANDA that the patent in question is invalid or is not infringed by the generic product”) patent challenges are a key element in the Hatch-Waxman framework for bringing generic drugs to market more quickly. While the focus on enabling access to affordable drugs has not changed, the state of the world has. As it has with many industries, the coronavirus global pandemic has ushered in extraordinary roadblocks for the pharmaceutical industry.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: